Approval of esketamine for treatment-resistant depression.,The Lancet Psychiatry

当前位置： X-MOL 学术 › Lancet Psychiatry › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Approval of esketamine for treatment-resistant depression.
The Lancet Psychiatry ( IF 30.8 ) Pub Date : 2020-03-01 , DOI: 10.1016/s2215-0366(19)30533-4
Jaskaran B Singh ₁ , Ella J Daly ₂ , Maju Mathews ₃ , Maggie Fedgchin ₄ , Vanina Popova ₅ , David Hough ₃ , Wayne C Drevets ₁

Affiliation

We acknowledge the questions raised by Erick Turner and by Ioana Cristea and Florian Naudet in The Lancet Psychiatry regarding esketamine's efficacy and the study designs within the phase 3 programme in treatment-resistant depression, and here provide clarification.

中文翻译：

批准艾司他明治疗难治性抑郁症。

我们承认《柳叶刀精神病学》杂志上的艾克特纳，艾可娜·克里斯泰（Ioana Cristea）和弗洛里安·诺德（Iriana Cristea）和弗洛里安·诺德（Florian Naudet）在依卡他敏的疗效以及抗药性抑郁症三期计划中的研究设计中提出的问题，在此进行澄清。

更新日期：2020-02-21

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文